A recent study reported encouraging results by fractionated GO combined with intensive chemotherapy in adult CD33+ AML patients relapsing after alloHCT, as salvage regimen, with an overall response rate of 72.0% and OS of 42.0% at 2 years [68]. The gene discussed is CD33; the disease is acute myeloid leukemia.